bepranemab
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
UCB presentation highlights impacts of epilepsy on daily life
The data underlines the consequences of disrupted sleep for patients and caregivers
UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency
TK2d is an extremely rare disease characterised by severe and progressive muscle weakness
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome
The study demonstrated a sustained reduction in seizures for patients
Lilly and WHO Foundation partner to support global dementia action plan
The partnership will provide financial support and strengthen early detection and intervention efforts
Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study
More than seven million people in the US are affected by the neurodegenerative disease
Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years
An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050
Roche shares promising data from Alzheimer’s disease development portfolio
The company is planning to initiate phase 3 studies of trontinemab in early AD this year
UCB shares promising results for fenfluramine in ultra-rare form of epilepsy
CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births
Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease
Planning is currently underway for a placebo-controlled trial of the candidate
Roche to advance Parkinson’s disease candidate into phase 3 development
More than ten million people worldwide are living with the neurodegenerative disorder